Sacubitril/Valsartan
- Generic Name
- Sacubitril/Valsartan
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
⑴用于在有慢性心力衰竭(NYHA类别II-IV)患者中减低对心力衰竭的心血管死亡及住院治疗慢性心力衰竭和射血分数降低。本品通常与其他心力衰竭治疗结合，代替一种ACE抑制药或其他血管紧张素II受体阻断药。
⑵用于治疗原发性高血压.
- Associated Conditions
- -
- Associated Therapies
- -
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2572
- Registration Number
- NCT03066804
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1009
- Registration Number
- NCT02957409
- Locations
- 🇨🇦
Novartis Investigative Site, Quebec, Canada
Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02788656
- Locations
- 🇺🇸
Brigham and Women's Hospita, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath